Persistence of multiple tumor-specific T-cell clones is associated with complete tumor regression in a melanoma patient receiving adoptive cell transfer therapy

Journal of Immunotherapy

Volumn 28, Issue 1, 2005, Pages 53-62

  Zhou, Juhua ^a   Dudley, Mark E ^a   Rosenberg, Steven A ^a,b   Robbins, Paul F ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b CRC   (United States)

Author keywords

Adoptive cell transfer; Melanoma; T cell persistence; T cell receptor beta chain variable regions; Tumor antigens

Indexed keywords

COMPLEMENTARY DNA; GLYCERALDEHYDE 3 PHOSPHATE DEHYDROGENASE; GROWTH ARREST SPECIFIC PROTEIN 6; GROWTH ARREST SPECIFIC PROTEIN 7; T LYMPHOCYTE ANTIGEN; T LYMPHOCYTE RECEPTOR BETA CHAIN; UNCLASSIFIED DRUG;

ADOPTIVE IMMUNOTHERAPY; ADOPTIVE TRANSFER; ANTIGEN SPECIFICITY; ARTICLE; AUTOTRANSPLANTATION; BLOOD; CANCER REGRESSION; GENE EXPRESSION; GENE IDENTIFICATION; GENE MUTATION; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; IN VIVO STUDY; LUNG METASTASIS; LYMPHOCYTE CLONE; MAJOR CLINICAL STUDY; MELANOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; SEQUENCE ANALYSIS; SOFT TISSUE METASTASIS; T LYMPHOCYTE; TUMOR ASSOCIATED LEUKOCYTE;

EID: 11344251911     PISSN: 15249557     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002371-200501000-00007     Document Type: Article

References (26)

1. Dudley ME, Wunderlich JR, Robbins PF, et al. Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science. 2002;298:850-854.
2. Rosenberg SA, Packard BS, Aebersold PM, et al. Use of tumor infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. Preliminary report. N Engl J Med. 1988;319:1676-1680.
3. Rosenberg SA, Yannelli JR, Yang JC, et al. Treatment of patients with metastatic melanoma with autologous tumor-infiltrating lymphocytes and interleukin 2. J Natl Cancer Inst. 1994;86:1159-1166.
4. Yee C, Thompson JA, Byrd D, et al. Adoptive T cell therapy using antigen-specific CD8+ T cell clones for the treatment of patients with metastatic melanoma: in vivo persistence, migration, and antitumor effect of transferred T cells. Proc Natl Acad Sci USA. 2002;99:16168-16173.
5. Huang J, El-Gamil M, Dudley ME, et al. T cells associated with tumor regression recognize frameshifted products of the CDKN2A tumor suppressor gene locus and a mutated HLA class I gene product. J Immunol. 2004;172:6057-6064.
6. Muller G, Lipp M. Shaping up adaptive immunity: the impact of CCR7 and CXCR5 on lymphocyte trafficking. Microcirculation. 2003;10:325-334.
7. Rosen SD. Ligands for L-selectin: homing, inflammation, and beyond. Annu Rev Immunol. 2004;22:129-156.
8. Meidenbauer N, Marienhagen J, Laumer M, et al. Survival and tumor localization of adoptively transferred Melan-A-specific T cells in melanoma patients. J Immunol. 2003;170:2161-2169.
9. Pisarra P, Mortarini R, Salvi S, et al. High frequency of T cell clonal expansions in primary human melanoma. Involvement of a dominant clonotype in autologous tumor recognition. Cancer Immunol Immunother. 1999;48:39-46.
10. Willhauck M, Scheibenbogen C, Pawlita M, et al. Restricted T-cell receptor repertoire in melanoma metastases regressing after cytokine therapy. Cancer Res. 2003;63:3483-3485.
11. Paschen A, Eichmuller S, Schadendorf D. Identification of tumor antigens and T-cell epitopes, and its clinical application. Cancer Immunol Immunother. 2004;53:196-203.
12. Renkvist N, Castelli C, Robbins PF, et al. A listing of human tumor antigens recognized by T cells. Cancer Immunol Immunother. 2001;50: 3-15.
13. Robbins PF, Kawakami Y. Human tumor antigens recognized by T cells. Curr Opin Immunol. 1996;8:628-636.
14. Rosenberg SA. Progress in the development of immunotherapy for the treatment of patients with cancer. J Intern Med. 2001;250:462-475.
15. Wang RF, Rosenberg SA. Human tumor antigens for cancer vaccine development. Immunol Rev. 1999;170:85-100.
16. Kawakami Y, Dang N, Wang X, et al. Recognition of shared melanoma antigens in association with major HLA-A alleles by tumor infiltrating T lymphocytes from 123 patients with melanoma. J Immunother. 2000; 23:17-27.
17. Robbins PF, El-Gamil M, Li YF, et al. A mutated b-catenin gene encodes a melanoma-specific antigen recognized by tumor infiltrating lymphocytes. J Exp Med. 1996;183:1185-1192.
18. Dudley ME, Wunderlich J, Shelton TE, et al. Generation of tumor-infiltrating lymphocyte cultures for use in adoptive transfer therapy for melanoma patients. J Immunother. 2003;26:332-342.
19. Rubio V, Stuge TB, Singh N, et al. Ex vivo identification, isolation and analysis of tumor-cytolytic T cells. Nat Med. 2003;9:1377-1382.
20. Dudley ME, Wunderlich J, Nishimura MI, et al. Adoptive transfer of cloned melanoma-reactive T lymphocytes for the treatment of patients with metastatic melanoma. J Immunother. 2001;24:363-373.
21. Ju YT, Chang AC, She BR, et al. gas7: a gene expressed preferentially in growth-arrested fibroblasts and terminally differentiated Purkinje neurons affects neunte formation. Proc Natl Acad Sci USA. 1998;95:11423-11428.
22. Megonigal MD, Cheung NK, Rappaport EF, et al. Detection of leukemia-associated MLL-GAS7 translocation early during chemotherapy with DNA topoisomerase II inhibitors. Proc Natl Acad Sci USA. 2000;97: 2814-2819.
23. So CW, Karsunky H, Passegue E, et al. MLL-GAS7 transforms multipotent hematopoietic progenitors and induces mixed lineage leukemias in mice. Cancer Cell. 2003;3:161-171.
24. She BR, Liou GG, Lin-Chao S. Association of the growth-arrest-specific protein Gas7 with F-actin induces reorganization of microfilaments and promotes membrane outgrowth. Exp Cell Res. 2002;273:34-44.
25. Brown VM, Krynetski EY, Krynetskaia NF, et al. A novel CRM1-mediated nuclear export signal governs nuclear accumulation of glyceraldehyde-3-phosphate dehydrogenase following genotoxic stress. J Biol Chem. 2004;279:5984-5992.
26. Zhong X, Ran YL, Lou JN, et al. Construction of human liver cancer vascular endothelium cDNA expression library and screening of the endothelium-associated antigen genes. World J Gastroenterol. 2004;10: 1402-1408.